Cosmo Bio USA’s portfolio of solid tumor oncology research products advances the understanding of the molecular events that drive solid tumors. The collection includes validated antibodies, ELISA kits, and recombinant proteins for some of the most critical oncogenes and tumor suppressors, including TP53, RB1, KRAS, BRAF, MYC, PTEN, and PIK3CA. These products allow researchers to probe mutations, phosphorylation states, and pathway dysregulation that contribute to unchecked proliferation and genomic instability. In addition, tools targeting receptor tyrosine kinases and signaling intermediates such as EGFR, HER2, MET, and ALK enable precise monitoring of oncogenic signaling networks central to tumor initiation, progression, and therapeutic resistance. By covering both upstream drivers and downstream effectors, the portfolio supports applications in biomarker discovery, pathway mapping, and the validation of targeted therapies across a broad range of solid tumors, including breast, lung, colorectal, pancreatic, and melanoma.
Explore the complete collection of reagents for the study of solid tumor oncology below.
